Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 16, 2010

Sigma-Aldrich Expands In Vivo Biology Offerings through Purchase of Ace Animals

  • Sigma-Aldrich is acquiring Ace Animals, a provider of research rodents to the biomedical industry. Ace Animals offers products and contract breeding services and will operate as part of Sigma Advanced Genetic Engineering (SAGE™) Labs.

    The acquisition will enhance SAGE Labs' current rat and mouse breeding capabilities, primarily used in the development and characterization of its next-generation knockout and knockin rat models featuring specific gene deletions, insertions, repressions, and modifications. These models are created using CompoZr™ Zinc Finger Nuclease technology.

    SAGE Labs’ portfolio of products and services now includes a number of wild-type rats and mice, including Swiss Webster, Sprague Dawley, ICR, Balb/c, C57BL/6, and Cotton Rats. In addition, the fact that Ace Animals is located in Berks County, PA, is expected to enhance distribution of SAGE Labs’ models to key sites within the U.S. biopharma industry.

    “With the Ace Animals acquisition, SAGE Labs will be in a better position to offer a greater number of models with the goal of helping researchers understand the functional significance of genes and their relationships to human diseases,” comments Edward Weinstein, Ph.D., director of SAGE Labs.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »